Nkarta
Update in progressNKTX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Nkarta, Inc. is a clinical-stage biopharma company developing natural killer (NK) cell therapies for cancer and autoimmune diseases. Its lead candidate, NKX019, is a CAR-NK therapy targeting CD19 and is in Phase 1 testing for lupus nephritis, systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis, systemic lupus erythematosus, and myasthenia gravis. The company collaborates with CRISPR Therapeutics and is based in South San Francisco, founded in 2015.
Company score
- Sentiment
- 0.14
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.04
- Governance
- -0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.07
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!